The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor [1]

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3431-

  Toyooka, Shinichi ^a   Date, Hiroshi ^a   Uchida, Akiko ^a   Kiura, Katsuyuki ^a   Takata, Minoru ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR D761Y; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLELE; CANCER SURGERY; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; LETTER; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MUTANT; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSIENT TRANSFECTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34250621361     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0070     Document Type: Letter

References (5)

1. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
2. Tokumo M, Toyooka S, Ichihara S, et al. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 2006;53:117-21.
3. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl JMed 2004;350:2129-39.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.